AMBER OWINGS: Open Payments
NPI 1205215167 · BLOOMINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$744 in 24 payments from 8 companies in 2025. Trend: 2023 $276 · 2024 $582 · 2025 $744
Food & beverage: $744
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $235 |
| Otsuka America Pharmaceutical, Inc. | 3 | $164 |
| ABBVIE INC. | 8 | $155 |
| Axsome Therapeutics, Inc. | 2 | $103 |
| Noven Therapeutics, LLC | 1 | $23 |
| Almatica Pharma LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Auvelity, Xelstrym, LOREEV XR, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
